Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a study evaluating durvalumab, an anti-PD-L1 antibody, and PET-directed chemoradiation (CRT) after induction FOLFOX for patients with esophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).